Younger women with breast cancer who had a mastectomy demonstrated a worse quality of life (QoL) compared with those who underwent breast-conserving surgery (BCS), according to a study presented at SABCS 2018.
Use of a scalp cooling device is effective in reducing alopecia or hair loss in patients with breast cancer who are undergoing neoadjuvant/adjuvant chemotherapy including anthracyclines* and taxanes**, according to studies presented at SABCS 2018.
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.
A structured cardiovascular (CV) exercise programme during adjuvant breast cancer treatment provides significant protection against decline in CV function related to chemotherapy-induced cardiotoxicity, according to the EBBA*-II trial presented at SABCS 2018, indicating that physical activity during treatment for breast cancer can benefit patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.